PGNY
Progyny, Inc.
$25.86
+1.49%
$2.0B
No data for this timeframe.
Vol
Market Cap$2.0B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders11 funds
Inst. Value$520.0M
Inst. Activity2 buys / 1 sells
Insider Activity0B / 9S
Insider Net $-$946.5K
SEC Reports9
Exchange Nasdaq·Sector Services-Misc Health & Allied Services, NEC·Inc. DE·CIK 0001551306·Prev Close $25.48
Recent Activity
Jun 5, 2026
SEC
Four Progyny insiders (CEO excluded) sold a total of ~$402K worth of common stock over a 7-day window, with no open-mark
CLUSTER — Impact 3/10
Jun 4, 2026
Insider
Livingston Mark S. sold 339 shares
CHIEF FINANCIAL OFFICER @ $24.99 ($8.5K)
Jun 4, 2026
Insider
Swartz Allison sold 599 shares
EVP, GC @ $25.08 ($15.0K)
Jun 4, 2026
Insider
Livingston Mark S. sold 1,918 shares
CHIEF FINANCIAL OFFICER @ $25.50 ($48.9K)
Jun 3, 2026
SEC
Two Progyny insiders (a director and the EVP/GC) sold a combined $198K in open-market sales over a 5-day window. The tot
CLUSTER — Impact 3/10
May 28, 2026
SEC
Progyny reported Q1 2026 EPS of $0.29 on revenue of $348.6M, sharply below consensus estimates of $0.52 and $348.6M resp
PRESS-RELEASE — Impact 6/10
Inst.
NORGES BANK — NEW
395,903 shares ($10.2M)
Inst.
WELLS FARGO & COMPANY/MN — ADD
94,448 shares ($2.4M)
Price Targets
$29.73
+15.0% upside
Buy
Current $25.86
Low $26.00
Median $30.00
High $31.00
11 analysts
$26.00
$31.00
Analyst Ratings
6Strong Buy
9Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
| May 19, 2026 | Canaccord Genuity | UPGRADE | Hold → Buy |
| May 18, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| May 11, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| May 11, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.52 ▲ +8.8% | $0.50 — $0.54 | 8% YoY | 7 |
| Next Q | $0.52 ▲ +5.7% | $0.50 — $0.55 | 16% YoY | 7 |
| Current FY | $2.06 ▲ +8.8% | $2.02 — $2.09 | 9% YoY | 7 |
| Next FY | $2.21 ▲ +5.0% | $1.97 — $2.47 | 7% YoY | 8 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Four Progyny insiders (CEO excluded) sold a total of ~$402K worth of common stock over a 7-day window, with no open-mark
Jun 5, 2026
NEUTRAL
CLUSTER
3/10
Two Progyny insiders (a director and the EVP/GC) sold a combined $198K in open-market sales over a 5-day window. The tot
Jun 3, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $247.4M | — |
| FMR LLC | $168.6M | ADD |
| MORGAN STANLEY | $33.0M | TRIM |
| RENAISSANCE TECHNOLOGIES LLC | $21.0M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $18.8M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Livingston Mark | F | $8.5K |
| Jun 4, 2026 | Swartz Allison | SELL | $15.0K |
| Jun 4, 2026 | Livingston Mark | SELL | $48.9K |
| Jun 4, 2026 | Swartz Allison | F | $8.5K |
| Jun 3, 2026 | Swartz Allison | F | $17.0K |
11 institutional holders with $520.0M total value (20,580,031 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 9,633,382 | $247.4M | 47.6% | — |
| 2 | FMR LLC | 6,566,910 | $168.6M | 32.4% | ADD +39.4% |
| 3 | MORGAN STANLEY | 1,286,631 | $33.0M | 6.4% | TRIM -49.6% |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 818,367 | $21.0M | 4.0% | ADD +37.7% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 732,431 | $18.8M | 3.6% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 679,387 | $17.4M | 3.4% | — |
| 7 | NORGES BANK | 395,903 | $10.2M | 2.0% | NEW |
| 8 | WELLS FARGO & COMPANY/MN | 94,448 | $2.4M | 0.5% | ADD +97.5% |
| 9 | TWO SIGMA INVESTMENTS, LP | 41,457 | $1.1M | 0.2% | NEAR_EXIT -75.2% |
| 10 | Duquesne Family Office LLC | 295,115 | $7.6K | 0.0% | — |
| 11 | Olstein Capital Management, L.P. | 36,000 | $924.00 | 0.0% | ADD +45.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 395,903 | — | $10.2M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 47,828 | 94,448 | +97.5% | $2.4M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 167,357 | 41,457 | -75.2% | $1.1M | 2025-Q4 |
| FMR LLC | ADD | 4,712,613 | 6,569,099 | +39.4% | $141.4M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 727,800 | 1,002,509 | +37.7% | $21.6M | 2025-Q3 |
| UBS Group AG | ADD | 149,496 | 243,541 | +62.9% | $5.2M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 37,235 | 47,828 | +28.4% | $1.0M | 2025-Q3 |
| Olstein Capital Management, L.P. | ADD | 24,000 | 35,000 | +45.8% | $753.00 | 2025-Q3 |
| NORGES BANK | EXIT | 77,126 | 0 | -100.0% | $0.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 727,800 | — | $16.0M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 322,508 | 169,692 | -47.4% | $3.7M | 2025-Q2 |
| UBS Group AG | ADD | 117,275 | 149,496 | +27.5% | $3.3M | 2025-Q2 |
| NORGES BANK | NEW | — | 77,126 | — | $1.7M | 2025-Q2 |
| FMR LLC | DOUBLED | 130,951 | 4,107,531 | +3036.7% | $91.8M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 577,921 | 1,363,091 | +135.9% | $30.5M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 2,434,864 | 1,228,221 | -49.6% | $27.4M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 657,276 | 322,508 | -50.9% | $7.2M | 2025-Q1 |
| UBS Group AG | TRIM | 277,190 | 117,275 | -57.7% | $2.6M | 2025-Q1 |
| UBS Group AG | TRIM | 393,681 | 277,190 | -29.6% | $4.8M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 28,737 | 39,593 | +37.8% | $683.0K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 673,446 | — | $11.3M | 2024-Q3 |
13 unique insiders with 9 transactions. Net insider value: -$946.5K ($0.00 bought, $946.5K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Livingston Mark S. | CHIEF FINANCIAL OFFICER | F | 339 | $24.99 | $8.5K |
| Jun 4, 2026 | Swartz Allison | EVP, GC | SELL | 599 | $25.08 | $15.0K |
| Jun 4, 2026 | Livingston Mark S. | CHIEF FINANCIAL OFFICER | SELL | 1,918 | $25.50 | $48.9K |
| Jun 4, 2026 | Swartz Allison | EVP, GC | F | 339 | $24.99 | $8.5K |
| Jun 3, 2026 | Swartz Allison | EVP, GC | F | 676 | $25.12 | $17.0K |
| Jun 3, 2026 | Livingston Mark S. | CHIEF FINANCIAL OFFICER | F | 1,082 | $25.12 | $27.2K |
| Jun 3, 2026 | Swartz Allison | EVP, GC | SELL | 1,199 | $25.02 | $30.0K |
| Jun 3, 2026 | Anevski Peter | CHIEF EXECUTIVE OFFICER | F | 5,361 | $25.12 | $134.7K |
| Jun 2, 2026 | Livingston Mark S. | CHIEF FINANCIAL OFFICER | SELL | 279 | $26.20 | $7.3K |
| Jun 2, 2026 | Livingston Mark S. | CHIEF FINANCIAL OFFICER | F | 158 | $26.20 | $4.1K |
| Jun 1, 2026 | Scott Cheryl | Director | M | 14,667 | $0.00 | $0.00 |
| Jun 1, 2026 | Scott Cheryl | Director | F | 7,228 | $26.38 | $190.7K |
| Jun 1, 2026 | Scott Cheryl | Director | M | 14,667 | $13.00 | $190.7K |
| Jun 1, 2026 | Scott Cheryl | Director | SELL | 7,439 | $26.39 | $196.3K |
| May 28, 2026 | Swartz Allison | EVP, GC | F | 1,352 | $25.48 | $34.4K |
| May 28, 2026 | Swartz Allison | EVP, GC | SELL | 2,398 | $25.46 | $61.1K |
| May 27, 2026 | GORDON KEVIN K | Director | SELL | 5,500 | $24.99 | $137.4K |
| May 27, 2026 | GORDON KEVIN K | Director | J | 2,526 | $0.00 | $0.00 |
| May 21, 2026 | Scott Cheryl | Director | A | 5,660 | $0.00 | $0.00 |
| May 21, 2026 | Payson Norman | Director | A | 5,660 | $0.00 | $0.00 |
| May 21, 2026 | Payson Norman | Director | A | 3,203 | $12.49 | $40.0K |
| May 21, 2026 | Scott Cheryl | Director | A | 27,119 | $0.00 | $0.00 |
| May 21, 2026 | MORRIS DEBRA L | Director | A | 5,660 | $0.00 | $0.00 |
| May 21, 2026 | MORRIS DEBRA L | Director | A | 3,203 | $12.49 | $40.0K |
| May 21, 2026 | HOLSTEIN ROGER C | Director | A | 6,792 | $0.00 | $0.00 |
| May 21, 2026 | Park Jeffrey G | Director | A | 7,924 | $0.00 | $0.00 |
| May 21, 2026 | Park Jeffrey G | Director | A | 5,205 | $12.49 | $65.0K |
| May 21, 2026 | HOLSTEIN ROGER C | Director | A | 4,003 | $12.49 | $50.0K |
| May 21, 2026 | GORDON KEVIN K | Director | A | 6,792 | $0.00 | $0.00 |
| May 21, 2026 | GORDON KEVIN K | Director | A | 30,373 | $0.00 | $0.00 |
| May 21, 2026 | Dean Lloyd H | Director | A | 6,792 | $0.00 | $0.00 |
| May 21, 2026 | Dean Lloyd H | Director | A | 28,203 | $0.00 | $0.00 |
| May 21, 2026 | Bierbower Elizabeth D | Director | A | 5,660 | $0.00 | $0.00 |
| May 21, 2026 | Bierbower Elizabeth D | Director | A | 3,203 | $12.49 | $40.0K |
| May 20, 2026 | Livingston Mark S. | CHIEF FINANCIAL OFFICER | SELL | 8,275 | $25.50 | $211.0K |
| May 19, 2026 | Cummings Melissa B | Chief Operating Officer | SELL | 9,578 | $25.00 | $239.4K |
| Apr 14, 2026 | Cummings Melissa B | Chief Operating Officer | F | 4,172 | $16.98 | $70.8K |
| Mar 17, 2026 | Clapp Geoffrey | Chief Product Officer | F | 3,275 | $17.42 | $57.1K |
| Mar 4, 2026 | Swartz Allison | EVP, GC | F | 339 | $17.52 | $5.9K |
| Mar 4, 2026 | Livingston Mark S. | CHIEF FINANCIAL OFFICER | F | 339 | $17.52 | $5.9K |
| Mar 3, 2026 | Anevski Peter | CHIEF EXECUTIVE OFFICER | F | 17,611 | $17.60 | $310.0K |
| Mar 2, 2026 | Clapp Geoffrey | Chief Product Officer | A | 51,373 | $0.00 | $0.00 |
| Mar 2, 2026 | Cummings Melissa B | Chief Operating Officer | A | 66,289 | $0.00 | $0.00 |
| Mar 2, 2026 | Anevski Peter | CHIEF EXECUTIVE OFFICER | A | 159,091 | $0.00 | $0.00 |
| Mar 2, 2026 | Anevski Peter | CHIEF EXECUTIVE OFFICER | A | 232,011 | $0.00 | $0.00 |
| Mar 2, 2026 | Clapp Geoffrey | Chief Product Officer | A | 35,228 | $0.00 | $0.00 |
| Mar 2, 2026 | Cummings Melissa B | Chief Operating Officer | A | 45,454 | $0.00 | $0.00 |
9 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 8 neutral. Avg impact: 3.1/10.
NEUTRAL
CLUSTER
3/10
Four Progyny insiders (CEO excluded) sold a total of ~$402K worth of common stock over a 7-day windo
Jun 5, 2026
NEUTRAL
CLUSTER
3/10
Two Progyny insiders (a director and the EVP/GC) sold a combined $198K in open-market sales over a 5
Jun 3, 2026
BEARISH
PRESS-RELEASE
6/10
Progyny reported Q1 2026 EPS of $0.29 on revenue of $348.6M, sharply below consensus estimates of $0
May 28, 2026
NEUTRAL
144
2/10
Director Kevin K. Gordon filed a Form 144 notice of intent to sell 5,500 shares of Progyny (PGNY) at
May 27, 2026
NEUTRAL
CLUSTER
3/10
CFO Livingston and COO Cummings collectively sold ~$450K of PGNY stock in open-market transactions o
May 26, 2026
NEUTRAL
8-K
4/10
Progyny announced a $200 million share repurchase program, funded from available cash. The program i
May 26, 2026
NEUTRAL
CLUSTER
2/10
Two C-suite insiders at Progyny (CFO and COO) sold a combined $450K in open-market sales over two da
May 21, 2026
NEUTRAL
PRESS-RELEASE
2/10
Progyny announced it will report Q1 2026 earnings on May 7, 2026, after market close. The press rele
Apr 23, 2026
NEUTRAL
DEFA14A
3/10
Analysis based on filing metadata only — document content was unavailable
Apr 10, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (88% buy). Based on 17 analysts: 6 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$29.73 mean target
+15.0% upside
Buy (1.36)
$26.00 Low
$31.00 High
| Metric | Value |
|---|---|
| Current Price | $25.86 |
| Target Low | $26.00 |
| Target Mean | $29.73 |
| Target Median | $30.00 |
| Target High | $31.00 |
| # Analysts | 11 |
| Recommendation | Buy (1.36) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.52 | $0.50 | $0.54 | 8.5% | +8.8% | 6↑ 0↓ | $0.3B | 4.7% | 7 |
| Next Q 2026-09-30 |
$0.52 | $0.50 | $0.55 | 16.3% | +5.7% | 7↑ 0↓ | $0.3B | 11.6% | 7 |
| Current FY 2026-12-31 |
$2.06 | $2.02 | $2.09 | 8.9% | +8.8% | 6↑ 0↓ | $1.4B | 7.3% | 7 |
| Next FY 2027-12-31 |
$2.21 | $1.97 | $2.47 | 7.2% | +5.0% | 6↑ 1↓ | $1.5B | 8.8% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.521 | |
| 7d ago | $0.521 | |
| 30d ago | $0.478 | +0.042 |
| 60d ago | $0.478 | +0.042 |
| 90d ago | $0.477 | +0.043 |
7 analyst firms have rated this stock: 2 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| May 19, 2026 | Canaccord Genuity | UPGRADE | Hold | Buy |
| May 18, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 11, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| May 11, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Mar 20, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 11, 2026 | Canaccord Genuity | MAINTAIN | Hold | Hold |
| Mar 5, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | Keybanc | MAINTAIN | Overweight | Overweight |
| Mar 2, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | Citizens | UPGRADE | Market Perform | Market Outperform |
| Jan 8, 2026 | Keybanc | MAINTAIN | Overweight | Overweight |
| Dec 9, 2025 | Barclays | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 9 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 6 | 8 | 3 | 0 | 0 | 82% | |
| Apr 1, 2026 | 6 | 8 | 3 | 0 | 0 | 82% | |
| Mar 1, 2026 | 6 | 8 | 3 | 0 | 0 | 82% | |
| Feb 1, 2026 | 6 | 8 | 3 | 0 | 0 | 82% | |
| Jan 1, 2026 | 6 | 6 | 5 | 0 | 0 | 71% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
short_volume
Short Volume: PGNY — 76.1% short (0.4M / 0.5M)
Short: 411,652 | Exempt: 1,246 | TRF Vol: 540,885 | Short Ratio: 76.1% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: PGNY — 64.4% short (0.5M / 0.8M)
Short: 523,457 | Exempt: 24,542 | TRF Vol: 812,548 | Short Ratio: 64.4% | Off-exchange volume (dark pool + OTC)
May 28, 2026
earnings
New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System
Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience <pre>Patients increasingly
May 20, 2026
short_volume
Short Volume: PGNY — 62.1% short (0.4M / 0.6M)
Short: 393,141 | Exempt: 0 | TRF Vol: 632,719 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
May 11, 2026
other
Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference
<p align="left">NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solut
May 7, 2026
earnings
Progyny, Inc. Announces First Quarter 2026 Results
<p align="center">Reports Record First Quarter Revenue of $328.5 Million<br>Early Selling Season Activity Reflects Robust Demand for Women's Health an
May 7, 2026
earnings_calendar
PGNY Q1 2026 Earnings Scheduled — 2026-05-07
Apr 27, 2026
short_volume
Short Volume: PGNY — 73.9% short (0.4M / 0.5M)
Short: 402,121 | Exempt: 25 | TRF Vol: 544,168 | Short Ratio: 73.9% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: PGNY — 75.6% short (0.4M / 0.5M)
Short: 395,117 | Exempt: 0 | TRF Vol: 522,679 | Short Ratio: 75.6% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
earnings
Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
<p align="left">NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building sol
Apr 22, 2026
short_volume
Short Volume: PGNY — 69.1% short (0.4M / 0.5M)
Short: 375,920 | Exempt: 131 | TRF Vol: 544,203 | Short Ratio: 69.1% | Off-exchange volume (dark pool + OTC)
Apr 16, 2026
other
Progyny Expands Access to Fertility and Women’s Health with Industry’s First Fully Insured Supplemental Plan
Progyny announces first-of-its-kind plan that expands access to comprehensive fertility benefits with predictable costs for small employers
Apr 1, 2026
other
Progyny Commemorates 10 Years of Redefining Women’s Health and Family Building Care
Throughout 2026, in partnership with members, providers, and employers, Progyny will highlight a decade of innovation, expanded access, and industry-l
Mar 23, 2026
short_volume
Short Volume: PGNY — 60.4% short (0.3M / 0.6M)
Short: 347,386 | Exempt: 411 | TRF Vol: 575,257 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
Mar 6, 2026
other
Progyny, Inc. Executives to Participate in Upcoming Investor Conferences
<p align="justify">NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building